Lefno 10 Tablet contains Leflunomide 10 mg, a disease-modifying antirheumatic drug (DMARD) primarily indicated for the treatment of active rheumatoid arthritis and psoriatic arthritis. Leflunomide exerts its therapeutic effect by inhibiting dihydroorotate dehydrogenase, a key enzyme involved in pyrimidine synthesis, thereby reducing the proliferation of activated lymphocytes responsible for inflammation and joint damage. This immunomodulatory action helps to alleviate symptoms such as joint pain, swelling, and stiffness, while also slowing disease progression and improving physical function. Lefno 10 is typically prescribed as part of a comprehensive treatment plan, which may include nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. It is important to monitor liver function tests and blood counts regularly during therapy due to potential hepatotoxicity and hematologic adverse effects. Lefno 10 should be used cautiously in patients with pre-existing liver disease or immunosuppression. Contraindications include pregnancy and severe hepatic impairment. Patients are advised to avoid pregnancy during and for a specified period after treatment due to teratogenic risks. Dose adjustments may be necessary based on clinical response and tolerability. Lefno 10 Tablet offers an effective option for managing autoimmune arthritis conditions, improving patient quality of life through targeted immunosuppression.